Elke Valk
Overview
Explore the profile of Elke Valk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
356
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wendler J, Lewis R, Kutilina A, Knott M, Isbell L, Valk E, et al.
Haematologica
. 2025 Jan;
PMID: 39844752
Not available.
2.
Isbell L, Uibeleisen R, Friedl A, Burger E, Dopatka T, Scherer F, et al.
BMC Cancer
. 2023 Aug;
23(1):767.
PMID: 37596517
Background: Older primary central nervous system lymphoma (PCNSL) patients have an inferior prognosis compared to younger patients because available evidence on best treatment is scarce and treatment delivery is challenging...
3.
Wendler J, Fox C, Valk E, Steinheber C, Fricker H, Isbell L, et al.
BMC Cancer
. 2022 Sep;
22(1):971.
PMID: 36088292
Background: Primary diffuse large B-cell lymphoma (DLBCL) of the central nervous system (PCNSL) is a rare disorder with an increasing incidence over the past decades. High-level evidence has been reported...
4.
Illerhaus G, Kasenda B, Ihorst G, Egerer G, Lamprecht M, Keller U, et al.
Lancet Haematol
. 2016 Aug;
3(8):e388-97.
PMID: 27476790
Background: High-dose methotrexate-based chemotherapy is standard for primary CNS lymphoma, but most patients relapse. High-dose chemotherapy with autologous stem cell transplantation (HCT-ASCT) is supposed to overcome the blood-brain barrier and...
5.
Schorb E, Finke J, Ferreri A, Ihorst G, Mikesch K, Kasenda B, et al.
BMC Cancer
. 2016 Apr;
16:282.
PMID: 27098429
Background: Primary central nervous system lymphoma (PCNSL) is a highly aggressive Non-Hodgkin lymphoma (NHL) with rising incidence over the past 30 years in immunocompetent patients. Although outcomes have improved, PCNSL...
6.
Banton M, Inder K, Valk E, Rudd C, Schneider H
Mol Cell Biol
. 2014 Feb;
34(8):1486-99.
PMID: 24515439
Despite playing a central role in tolerance, little is known regarding the mechanism by which intracellular CTLA-4 is shuttled from the trans-Golgi network to the surfaces of T cells. In...
7.
Schneider H, Valk E, Leung R, Rudd C
PLoS One
. 2008 Dec;
3(12):e3842.
PMID: 19052636
The balance of T-cell proliferation, anergy and apoptosis is central to immune function. In this regard, co-receptor CTLA-4 is needed for the induction of anergy and tolerance. One central question...
8.
Valk E, Rudd C, Schneider H
Trends Immunol
. 2008 May;
29(6):272-9.
PMID: 18468488
The T-cell co-receptor cytotoxic T-cell antigen 4 (CTLA-4) has a strong inhibitory role as shown by the lymphoproliferative phenotype of CTLA-4-deficient mice. Despite its potent effects on T-cell function, CTLA-4...
9.
Schneider H, Wang H, Raab M, Valk E, Smith X, Lovatt M, et al.
PLoS One
. 2008 Mar;
3(3):e1718.
PMID: 18320039
While the adaptor SKAP-55 mediates LFA-1 adhesion on T-cells, it is not known whether the adaptor regulates other aspects of signaling. SKAP-55 could potentially act as a node to coordinate...
10.
Valk E, Leung R, Kang H, Kaneko K, Rudd C, Schneider H
Immunity
. 2006 Oct;
25(5):807-21.
PMID: 17070077
The costimulatory molecule CTLA-4 is a potent downregulator of T cell responses. Although localized mostly in intracellular compartments, little is understood regarding the mechanism that regulates its transport to the...